Adaptive Biotechnologies (NASDAQ:ADPT) Stock: Insider Susan Bobulsky Sells 1,875 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) insider Susan Bobulsky sold 1,875 shares of the firm’s stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $32.00, for a total value of $60,000.00. Following the completion of the sale, the insider owned 387,475 shares of the company’s stock, valued at approximately $12,399,200. This trade represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

  • On Tuesday, October 6th, Susan Bobulsky sold 6,444 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $30.00, for a total value of $193,320.00.
  • On Tuesday, September 15th, Susan Bobulsky sold 1,195 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $27.00, for a total transaction of $32,265.00.

Adaptive Biotechnologies Price Performance

NASDAQ ADPT traded down $0.44 on Friday, hitting $29.04. 2,063,725 shares of the company were exchanged, compared to its average volume of 2,197,728. Adaptive Biotechnologies Corporation has a 1-year low of $12.00 and a 1-year high of $32.21. The firm has a 50 day moving average of $26.91 and a two-hundred day moving average of $20.13. The company has a current ratio of 3.97, a quick ratio of 3.87 and a debt-to-equity ratio of 1.82. The company has a market cap of $4.70 billion, a P/E ratio of -64.53 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.12. Adaptive Biotechnologies had a negative net margin of 23.67% and a negative return on equity of 23.95%. The firm had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $71.57 million. During the same quarter last year, the company posted $0.06 EPS. The company’s quarterly revenue was down 10.7% compared to the same quarter last year. On average, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.24 EPS for the current year.

Institutional Trading of Adaptive Biotechnologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in ADPT. Nykredit A S bought a new position in shares of Adaptive Biotechnologies in the 2nd quarter valued at about $31,000. Allworth Financial LP bought a new stake in shares of Adaptive Biotechnologies during the second quarter worth approximately $35,000. Integrated Wealth Concepts LLC bought a new stake in shares of Adaptive Biotechnologies during the second quarter worth approximately $46,000. KBC Group NV bought a new stake in shares of Adaptive Biotechnologies during the first quarter worth approximately $45,000. Finally, Assetmark Inc. lifted its holdings in Adaptive Biotechnologies by 46.4% in the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock valued at $61,000 after buying an additional 1,401 shares during the period. 99.17% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on ADPT. BTIG Research raised their price target on shares of Adaptive Biotechnologies from $25.00 to $34.00 and gave the company a “buy” rating in a report on Tuesday, September 22nd. TD Cowen upped their price objective on Adaptive Biotechnologies from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. The Goldman Sachs Group initiated coverage on Adaptive Biotechnologies in a report on Tuesday, September 29th. They set a “buy” rating and a $35.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Thursday, October 15th. Finally, Piper Sandler lifted their target price on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.31.

Read Our Latest Report on Adaptive Biotechnologies

About Adaptive Biotechnologies

(Get Free Report)

Adaptive Biotechnologies is a biotechnology company focused on using the human immune system to diagnose and treat disease. Based in Seattle, Washington, the company develops technologies that sequence and analyze immune cells and their receptors, generating data for clinical testing, research and drug development. Its products include immunoSEQ, a platform used by researchers and biopharmaceutical companies to study immune responses, and clonoSEQ, a clinical test that detects and monitors minimal residual disease in certain blood cancers.

Recommended Stories

Insider Buying and Selling by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.